First‐in‐human study of blood amyloid β removal from early Alzheimer's disease patients with normal kidney function. Issue 3 (21st March 2022)

• Record Type: Journal Article
• Authors: Hasegawa, Midori; Kitaguchi, Nobuya; Takechi, Hajime; Kawaguchi, Kazunori; Ito, Kengo; Kato, Takashi; Kato, Masao; Nii, Norio; Yamada, Sachie; Ohashi, Atsushi; Koide, Shigehisa; Hayashi, Hiroki; Takahashi, Kazuo; Inaguma, Daijo; Yuzawa, Yukio; Tsuboi, Naotake
• Is Part Of: Therapeutic apheresis and dialysis. Volume 26:Issue 3(2022)
• Page Start: 529
• Page End: 536
• Publication Date: 2022-03-21
• Subjects: Alzheimer's disease -- amyloid β -- Aβ -- hemadsorption -- hexadecyl‐alkylated cellulose beads column; Hemapheresis -- Periodicals; Dialysis -- Periodicals; Blood Component Removal -- Periodicals; Renal Dialysis -- Periodicals; Hémaphérèse -- Périodiques; Dialyse -- Périodiques; Sang -- Collecte et conservation -- Périodiques; 616
• DOI: 10.1111/1744-9987.13827
• Languages: English
• ISSNs: 1744-9979

Abstract

Abstract: Introduction: Amyloid β (Aβ) is a brain protein that causes Alzheimer's disease (AD). This study aimed to verify whether hemadsorption using a hexadecyl‐alkylated cellulose bead (HexDC) column removes blood Aβ and brain Aβ accumulation in mild cognitive impairment/mild AD cases with normal kidney function. Methods: Two patients with positive Aβ on brain imaging underwent HexDC hemadsorption weekly for 6 months. Results: The Aβ removal efficiency of HexDC was 87–99%. Aβ1−40 /Aβ1−42 influx into the blood in one session was 596/56 and 489/48 ng for Case A and Case B, respectively. Although brain Aβ accumulation did not clearly change after 6 months of hemadsorption, cognitive functions measured by the two tests were maintained or slightly improved. Conclusion: Blood Aβ removal was performed in two early AD patients with normal kidney function without adverse events, and it slightly improved or maintained cognitive function.